Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma

American Journal of Dermatopathology

Volumn 27, Issue 5, 2005, Pages 401-406

  Reinke, Susanne ^a   Königer, Peter ^b   Herberth, Gunda ^a   Audring, Heike ^a   Wang, Hao ^c   Ma, Jing ^c   Quo, Yajun ^c   Sterry, Wolfram ^a   Trefzer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CHIETI   (Italy)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

A103; Immunohistochemistry; MART 1; Melanoma; SM5 1; T311; Tyrosinase

Indexed keywords

MELAN A; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HMB 45; MONOCLONAL ANTIBODY S100; MONOCLONAL ANTIBODY SM5 1; MONOPHENOL MONOOXYGENASE; PARAFFIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; PRIORITY JOURNAL; SKIN DISEASE;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MONOPHENOL MONOOXYGENASE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 25644456721     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.dad.0000180076.17932.ee     Document Type: Article

References (19)

1. Ordonez NG, Ji XL, Hickey RC. Comparison of HMB-45 monoclonal antibody and S100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol. 1988;90:385-390.
2. Trefzer U, Rietz R, Chen Y, et al. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res. 2000;292:583-589.
3. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues. Am J Surg Pathol. 1998;22:595-602.
4. Chen YT, Stockert E, Tsang S, et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA. 1995;92:8125-8129.
5. Hofbauer GF, Kamarashev J, Geertsen R, et al. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res. 1998;84:337-343.
6. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740-746.
7. Jungbluth AA, Iversen K, Coplan K, et al. T311-an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues. Pathol Res Pract. 2000;196:235-242.
8. Fetsch PA, Riker AI, Marincola FM, et al. Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma. Cancer. 2000;90:252-257.
9. Hofbauer GF, Kamarashev J, Geertsen R, et al. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. J Cutan Pathol. 1998;25:204-209.
10. Cormier JN, Abati A, Fetsch P, et al. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother. 1998;21:27-31.
11. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma: comparison with four other melanoma markers. Am J Surg Pathol. 2001;25:205-211.
12. Giorno RA. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol. 1984;2:161-166.
13. Busam KJ, Chen YT, Old LJ, et al. Expression of MART-1 (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982.
14. Kageshita T, Kawakami Y, Hirai S, et al. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother. 1997;20:460-465.
15. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology. 1998;32:139-146.
16. Jäger E, Ringhoffer M, Ahmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class 1 and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 1997;71:142-147.
17. de Vries TJ, Fourkour A, Wobbes T, et al. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Rex. 1997;57:3223-3229.
18. Slingluff CL, Colella TA, Thompson L, et al. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunol Immunother. 2000;48:661-672.
19. De Vries TJ, Smeets M, de Graad R, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol. 2001;193:13-20.